Interestingly, in the younger and older cohorts, antecedent MPN was a positive prognostic factor, possibly reflecting the widespread and highly effective use of BCR-ABL inhibitors in patients with AML with BCR-ABL translocations or perhaps a generally slower course of AML in diseases with antecedent MPN. The gene discussed is ABL1; the disease is myeloproliferative disorder.